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A Commentary on
The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression
during obesity
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Non-alcoholic fatty liver disease (NAFLD) is a multi-faceted and multi-factorial hepatic disease,
characterized by different patterns of histological damage, which range from hepatosteatosis to
non-alcoholic steatohepatitis (NASH). NASH is histologically characterized by hepatosteatosis,
hepatocellular ballooning, lobular inflammation, and fibrosis, which may progress to cirrhosis and,
potentially, end-stage liver disease and hepatocellular carcinoma (Yeh and Brunt, 2014).
It is widely accepted that NAFLD could be a heritable disease in which genetic variants,
including those of PNPLA3, TM6SF2, and MBOAT7 genes, and epigenetic drivers linked to over-
nutrition closely interact to determine the disease phenotype and its progression (Eslam et al.,
2018). Thus, epigenetic modifications, including chromatin remodeling, histone modifications,
DNA methylation and non-coding RNAs, make a major contribution in determining the NAFLD
onset and progression (Eslam et al., 2018). A genome-wide integrated methylome/transcriptome
analysis has demonstrated that genes involved in the methylation process, inflammation, and
fibrogenesis showed a stage-dependent regulation, suggesting that epigenetic changes are involved
in the progression of NAFLD (Murphy et al., 2013).
The recently-emerged fact that nutritional epigenetics may explain the gene-diet interactions,
further elucidating the modulatory role of nutrition in diseases, is noteworthy. In line, NAFLD
may exhibit a different pattern and level of severity of tissue damage in function of the excess
of specific nutrients in the diet. Several studies have showed that histone modifications, such
as acetylation and methylation, may contribute to diverse diet-induced metabolic dysfunctions
(Murphy et al., 2013). However, a comprehensive analysis of the histone modifications and their
dynamic changes in NAFLD is infrequent, hampering our understanding of the role of diet-related
epigenetic mechanisms in the development and progression of this disease.
In this regard, a recent article published in Nature Communication (Bricambert et al., 2018)
demonstrated that the histone demethylase Plant homeodomain finger 2 (Phf2) protects liver from
NAFLD progression. The authors found that an over-expression/induction of Phf2 protected the
liver from lipotoxicity and oxidative stress in models of a high-fat/high-sucrose diet (HF/HSD)
dependent NAFLD. The proposed mechanism was that a Phf2 over-expression regulated the
promoters of several genes including PKLR, ACLY, ACCA, FASN, SCD1, ELOVL6, TXNIP, RGS16,
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FIGURE 1 | Schematic representation of the Phf2 action in NAFLD. Phf2 activation, through H3K9me2 demethylation at specific ChREBP-regulated gene promoters,
increases MUFA synthesis and provides protection from the progression of hepatosteatosis toward NASH. Therapy based on Phf2, in combination with a low-caloric
diet and physical exercise could be an active therapeutic approach against NAFLD.
PNPLA3, and FGF21 by facilitating H3K9me2 histone
demethylation at a carbohydrate-responsive element binding
protein (ChREBP). Previous studies investigated the Phf2
role in metabolism (Baba et al., 2011; Okuno et al., 2013).
Baba et al. (2011) suggested that Phf2 is inactive by itself,
but becomes an active H3K9Me2 demethylase through PKA-
mediated phosphorylation, with a major role in the induction of
gluconeogenic genes (Baba et al., 2011). More recently, Okuno
et al. (2013) demonstrated a role for Phf2, in the regulation of
adipogenesis. Specifically, the authors demonstrated in Phf2-
knockout mice, that Phf2 potentiates adipogenesis through an
interaction with the transcription factor, the CCAAT/enhancer-
binding protein alpha, indicating Phf2 as a potential new
therapeutic target in the treatment of obesity and the metabolic
syndrome (Okuno et al., 2013).
Importantly, the article by Bricambert et al. (2018) fits well
into the deepening of the role of Phf2 in metabolic diseases.
Specifically, in a mouse model of HF/HSD-induced NAFLD, the
authors demonstrated that even by the triggering of diet-induced
hepatic steatosis, Phf2 concomitantly reduced lipotoxicity by
increasing the production of mono-unsaturated fatty acids
(MUFA), thus enhancing the MUFA/saturated fatty acids (SFA)
ratio. Phf2 over-expression also reduced oxidative stress by
improving the activity of the NF-E2-related factor 2 (Nrf2).
Findings by Bricambert et al. (2018) highlighted that both Phf2
and ChREBP are functionally co-recruited to the Nrf2 promoter
in response to glucose, thus increasing the Nrf2 expression and
its activity on the genes of specific targets. Indeed, the authors
reported that the Phf2-mediated activation of Nrf2, redirects
glucose toward the pentose phosphate pathway and glutathione
biosynthesis, defending the liver from the accumulation of
reactive oxygen species and consequently, oxidative stress.
The Phf2-dependent reduction of oxidative stress rebounded
like a cascade on several other genes that control hepatic
inflammation and fibrosis, implying a consequent great
reduction of their expression. Previous studies highlighted the
crucial role of Nrf2 and its signaling pathways in protecting
hepatic cells from oxidative damage during the development of
common chronic liver diseases, indicating Nrf2 as a therapeutic
target (Meakin et al., 2014; Sharma et al., 2017). Meakin
et al. (2014) showed that Nrf2 deficiency made the mice
more sensitive to develop NASH when placed on an HFD,
by the induction of lipogenesis genes and the suppression of
β-oxidation genes. More recently, the same group of authors
(Sharma et al., 2017) demonstrated that a potent pharmacologic
activator of Nrf2 (TBE-31) ameliorated experimental NASH
and liver fibrosis reducing insulin resistance, suppressing
hepatic steatosis, and inhibiting inflammatory response and
oxidative stress. However, the existence of some adverse effects
of Nrf2 activation cannot be ignored. In fact, among others,
a phase 3 clinical trial, evaluating the Nrf2-pathway activator
Bardoxolone methyl, in type 2 diabetes and stage 4 chronic
kidney disease, has been interrupted as it did not reduce the risk
of end-stage renal disease/death from cardiovascular causes (de
Zeeuw et al., 2013). These findings are important, considering
that Phf2 acts on Nrf2. Moreover, the fact that a Phf2 over-
expression promotes hepatic fat accumulation should not be
underestimated.
Several prevailing drugs, evaluated in clinical trials on NASH
patients have been proven to slightly improve only one feature of
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the hepatic disease without exacerbating the others (Townsend
and Newsome, 2017).
On the other hand, the Phf2-dependent increase of
hepatosteatosis is a no-progressive feature in the pre-clinical
study by Bricambert et al. (2018), suggesting the possibility to
employ Phf2 pharmaceutical targeting as a therapeutic approach.
Hopefully it might be hypothesized that the anti-
fibrogenic/inflammatory therapies based on Phf2 activation
could be an option, in combination with diet, physical exercise
and nutritional supplements that are recognized as anti-steatotic
(Figure 1) (Romero-Gómez et al., 2017).
In conclusion, the article by Bricambert et al. (2018)
provides a great contribution to the large landscape of
epigenetics, and could serve as another brick in the field
dealing with the use of epigenetic drugs as one of the multiple
treatments to be included in multi-target therapeutic strategies
in our fight against the development and progression of
NAFLD.
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